We’ve brought attention back to a repeat winner that we’ve covered for the better part of the last 4 years. Those of you who have been with us for a little while, you will surely remember OXIS International, now trading under the symbol (GTBP) we have once again begun to follow progress in the market. With past numerous examples of frequent breakouts, we once again see (GTBP) in appearing ready to break out.
Each time (GTBP) has pulled back to monthly lows, the market has responded positively and with recent news of the company’s CMO being promoted to CEO and Chairman of the Board, sentiment could continue to remain very positive.
As you can see, (GTBP) has once again begun to break out. The last time it did this, (GTBP) managed to rally to highs of over $2.70! Could this be in store once again? Well, as of today, we’ve not only seen (GTBP) rally 20% on an intra-day time frame but over the last 5 trading sessions, (GTBP) has moved up by as much as 53%! In our strong opinion, this could once again be the first sign of a much longer-term bull run.
We saw it back in June, we saw a “mini-rally” back in May, and we saw a test of the $2.25 level when (GTBP) ran in April. Ultimately it comes down to the fundamentals and with the small-cap biotech segment of the market taking much of the spotlight this year, 2018’s second half could be primed for companies like this to capitalize on the overall market momentum.
Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and GT Biopharma, Midam has been paid $200,000 from the company and ZERO shares of GT Biopharma Inc. for a duration beginning July 16, 2018 and ending August 16, 2018. Midam Ventures has been paid an additional $200k by GT Biopharma and has extended its marketing period through Sept 16, 2018. We may buy or sell additional shares of (GTBP) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Full Disclaimer Here
When investing one can never make assumptions. Investors must complete extensive due diligence before participating in the buying or selling of any security. It is important to look for proven management teams, serious scientific information and solid drug candidate development plans before investing in any biotech company.
The information in this article is historical fact and accurate stock market data. When considering investments in development stage companies as individual investors we must make certain we do not fall prey speculative, misleading or any information brazenly hyping the stock of any individual company.
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | email@example.com